• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

冠心病的一级和二级预防:综述

Primary and Secondary Prevention of CAD: A Review.

作者信息

Short Lindsay, La Van T, Patel Mandira, Pai Ramdas G

机构信息

Cardiology, University of California, Riverside, School of Medicine of California Riverside School of Medicine, Riverside, California.

St Bernadine Medical Center, Cardiology, Internal Medicine, San Bernardino, California.

出版信息

Int J Angiol. 2021 Dec 24;31(1):16-26. doi: 10.1055/s-0041-1729925. eCollection 2022 Mar.

DOI:10.1055/s-0041-1729925
PMID:35221848
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8881111/
Abstract

Coronary artery disease is the leading cause of death in both men and women, yet adequate control of risk factors can largely reduce the incidence and recurrence of cardiac events. In this review, we discuss various life style and pharmacological measures for both the primary and secondary prevention of coronary artery disease. With a clear understanding of management options, health care providers have an excellent opportunity to educate patients and ameliorate a significant burden of morbidity and mortality.

摘要

冠状动脉疾病是男性和女性的主要死因,然而对危险因素的充分控制可以在很大程度上降低心脏事件的发生率和复发率。在本综述中,我们讨论了冠状动脉疾病一级和二级预防的各种生活方式和药物治疗措施。清楚了解管理方案后,医疗保健提供者有绝佳机会对患者进行教育,并减轻发病率和死亡率的重大负担。

相似文献

1
Primary and Secondary Prevention of CAD: A Review.冠心病的一级和二级预防:综述
Int J Angiol. 2021 Dec 24;31(1):16-26. doi: 10.1055/s-0041-1729925. eCollection 2022 Mar.
2
Prevention of ventricular fibrillation, acute myocardial infarction (myocardial necrosis), heart failure, and mortality by bretylium: is ischemic heart disease primarily adrenergic cardiovascular disease?溴苄铵对室颤、急性心肌梗死(心肌坏死)、心力衰竭及死亡率的预防作用:缺血性心脏病主要是肾上腺素能心血管疾病吗?
Am J Ther. 2004 Sep-Oct;11(5):366-411. doi: 10.1097/01.mjt.0000126444.24163.81.
3
Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial.CT 血管造影筛查对糖尿病高危患者死亡率和心脏事件的影响:FACTOR-64 随机临床试验。
JAMA. 2014 Dec 3;312(21):2234-43. doi: 10.1001/jama.2014.15825.
4
Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.低分子量肝素治疗冠状动脉疾病不稳定期,冠状动脉疾病不稳定期使用法安明(FRISC)研究组
Lancet. 1996 Mar 2;347(9001):561-8.
5
API expert consensus document on management of ischemic heart disease.缺血性心脏病管理的API专家共识文件
J Assoc Physicians India. 2006 Jun;54:469-80.
6
Effect of Cerebrovascular and/or Peripheral Artery Disease With or Without Attainment of Lipid Goals on Long-Term Outcomes in Patients With Coronary Artery Disease.脑血管病和/或外周动脉疾病患者降脂目标达标与未达标对冠状动脉疾病患者长期预后的影响。
Am J Cardiol. 2020 Aug 1;128:28-34. doi: 10.1016/j.amjcard.2020.04.043. Epub 2020 May 13.
7
Management and clinical outcome of stable coronary artery disease in Austria : Results from 5 years of the CLARIFY registry.奥地利稳定型冠状动脉疾病的管理与临床结局:CLARIFY注册研究5年结果
Wien Klin Wochenschr. 2017 Dec;129(23-24):879-892. doi: 10.1007/s00508-017-1248-1. Epub 2017 Sep 14.
8
9
A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events).英国心脏病学会关于冠心病二级预防潜力的调查:ASPIRE(通过干预减少事件进行二级预防行动)。
Heart. 1996 Apr;75(4):334-42. doi: 10.1136/hrt.75.4.334.
10
Nitrates for the prevention of cardiac morbidity and mortality in patients undergoing non-cardiac surgery.硝酸盐类药物用于预防非心脏手术患者的心脏发病率和死亡率。
Cochrane Database Syst Rev. 2016 Aug 4;2016(8):CD010726. doi: 10.1002/14651858.CD010726.pub2.

引用本文的文献

1
Molecular Insights into the Potential Cardiometabolic Effects of GLP-1 Receptor Analogs and DPP-4 Inhibitors.胰高血糖素样肽-1受体类似物和二肽基肽酶-4抑制剂潜在心脏代谢效应的分子见解
Int J Mol Sci. 2025 Jul 15;26(14):6777. doi: 10.3390/ijms26146777.
2
Non-traditional lipid biomarkers in atherosclerotic cardiovascular disease: pathophysiological mechanisms and strategies to address residual risk.动脉粥样硬化性心血管疾病中的非传统脂质生物标志物:病理生理机制及应对残余风险的策略
Front Endocrinol (Lausanne). 2025 Jul 10;16:1576602. doi: 10.3389/fendo.2025.1576602. eCollection 2025.
3
Health information-seeking behavior in patients with coronary artery disease: Activating methods.冠心病患者的健康信息寻求行为:激活方法。
PLoS One. 2024 Apr 17;19(4):e0300755. doi: 10.1371/journal.pone.0300755. eCollection 2024.
4
Chemical Synthesis, Biological Evaluation, and Cheminformatics Analysis of a Group of Chlorinated Diaryl Sulfonamides: Promising Inhibitors of Cholesteryl Ester Transfer Protein.一组氯化二芳基磺酰胺的化学合成、生物学评价及化学信息学分析:胆固醇酯转移蛋白的潜在抑制剂
Curr Comput Aided Drug Des. 2024 Feb 27. doi: 10.2174/0115734099292078240218095540.
5
Updates in the Management of Coronary Artery Disease: A Review Article.冠状动脉疾病管理的最新进展:一篇综述文章。
Cureus. 2023 Dec 16;15(12):e50644. doi: 10.7759/cureus.50644. eCollection 2023 Dec.

本文引用的文献

1
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.恩格列净对伴或不伴糖尿病的心力衰竭患者心血管和肾脏结局的影响:来自 EMPEROR-Reduced 试验的结果。
Circulation. 2021 Jan 26;143(4):337-349. doi: 10.1161/CIRCULATIONAHA.120.051824. Epub 2020 Nov 11.
2
Performance of the Pooled Cohort Equations to Estimate Atherosclerotic Cardiovascular Disease Risk by Body Mass Index.基于体重指数的 pooled cohort equations 评估动脉粥样硬化性心血管疾病风险的性能。
JAMA Netw Open. 2020 Oct 1;3(10):e2023242. doi: 10.1001/jamanetworkopen.2020.23242.
3
Enriched Marine Oil Supplements Increase Peripheral Blood Specialized Pro-Resolving Mediators Concentrations and Reprogram Host Immune Responses: A Randomized Double-Blind Placebo-Controlled Study.富含海洋油的补充剂增加外周血特异性促解决介质的浓度并重新编程宿主免疫反应:一项随机双盲安慰剂对照研究。
Circ Res. 2020 Jan 3;126(1):75-90. doi: 10.1161/CIRCRESAHA.119.315506. Epub 2019 Dec 12.
4
Association of Animal and Plant Protein Intake With All-Cause and Cause-Specific Mortality in a Japanese Cohort.动物蛋白和植物蛋白摄入与日本队列全因和死因特异性死亡的关联。
JAMA Intern Med. 2019 Nov 1;179(11):1509-1518. doi: 10.1001/jamainternmed.2019.2806.
5
Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127 477 Participants.海洋 ω-3 补充剂与心血管疾病:涉及 127477 名参与者的 13 项随机对照试验的更新荟萃分析。
J Am Heart Assoc. 2019 Oct;8(19):e013543. doi: 10.1161/JAHA.119.013543. Epub 2019 Sep 30.
6
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.达格列净治疗射血分数降低的心力衰竭患者。
N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19.
7
Effects of Tobacco Smoking on Cardiovascular Disease.吸烟对心血管疾病的影响。
Circ J. 2019 Sep 25;83(10):1980-1985. doi: 10.1253/circj.CJ-19-0323. Epub 2019 Aug 29.
8
Atherosclerotic Cardiovascular Disease Risk Prediction in Disaggregated Asian and Hispanic Subgroups Using Electronic Health Records.利用电子健康记录对亚组化的亚洲和西班牙裔人群进行动脉粥样硬化性心血管疾病风险预测。
J Am Heart Assoc. 2019 Jul 16;8(14):e011874. doi: 10.1161/JAHA.118.011874. Epub 2019 Jul 11.
9
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.2019美国心脏病学会/美国心脏协会心血管疾病一级预防指南:美国心脏病学会/美国心脏协会临床实践指南工作组报告
Circulation. 2019 Sep 10;140(11):e596-e646. doi: 10.1161/CIR.0000000000000678. Epub 2019 Mar 17.
10
Dietary Restrictions and Nutrition in the Prevention and Treatment of Cardiovascular Disease.饮食限制与营养在心血管疾病的预防和治疗中的作用。
Circ Res. 2019 Mar 15;124(6):952-965. doi: 10.1161/CIRCRESAHA.118.313352.